Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

MicroRNAs Expression in Response to rhNGF in Epithelial Corneal Cells: Focus on Neurotrophin Signaling Pathway.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • المصدر:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: Basel, Switzerland : MDPI, [2000-
    • الموضوع:
    • نبذة مختصرة :
      Purpose: Nerve growth factor efficacy was demonstrated for corneal lesions treatment, and recombinant human NGF (rhNGF) was approved for neurotrophic keratitis therapy. However, NGF-induced molecular responses in cornea are still largely unknown. We analyzed microRNAs expression in human epithelial corneal cells after time-dependent rhNGF treatment.
      Methods: Nearly 700 microRNAs were analyzed by qRT-PCR. MicroRNAs showing significant expression differences were examined by DIANA-miRpath v.3.0 to identify target genes and pathways. Immunoblots were performed to preliminarily assess the strength of the in silico results.
      Results: Twenty-one microRNAs (miR-26a-1-3p, miR-30d-3p, miR-27b-5p, miR-146a-5p, miR-362-5p, mir-550a-5p, mir-34a-3p, mir-1227-3p, mir-27a-5p, mir-222-5p, mir-151a-5p, miR-449a, let7c-5p, miR-337-5p, mir-29b-3p, miR-200b-3p, miR-141-3p, miR-671-3p, miR-324-5p, mir-411-3p, and mir-425-3p) were significantly regulated in response to rhNGF. In silico analysis evidenced interesting target genes and pathways, including that of neurotrophin, when analyzed in depth. Almost 80 unique target genes (e.g., PI3K, AKT, MAPK, KRAS, BRAF, RhoA, Cdc42, Rac1, Bax, Bcl2, FasL ) were identified as being among those most involved in neurotrophin signaling and in controlling cell proliferation, growth, and apoptosis. AKT and RhoA immunoblots demonstrated congruence with microRNA expression, providing preliminary validation of in silico data.
      Conclusions: MicroRNA levels in response to rhNGF were for the first time analyzed in corneal cells. Novel insights about microRNAs, target genes, pathways modulation, and possible biological responses were provided. Importantly, given the putative role of microRNAs as biomarkers or therapeutic targets, our results make available data which might be potentially exploitable for clinical applications.
    • References:
      Cell Mol Life Sci. 2001 May;58(5-6):748-59. (PMID: 11437236)
      Sci Rep. 2019 Oct 3;9(1):14272. (PMID: 31582785)
      Biochem Biophys Res Commun. 2009 Jan 9;378(2):259-63. (PMID: 19026611)
      Nucleic Acids Res. 2015 Jul 1;43(W1):W460-6. (PMID: 25977294)
      PLoS One. 2011 Jan 17;6(1):e16132. (PMID: 21264230)
      PLoS One. 2014 Dec 09;9(12):e114692. (PMID: 25490205)
      PLoS One. 2013 Nov 26;8(11):e79926. (PMID: 24302991)
      Int J Mol Sci. 2018 Feb 04;19(2):. (PMID: 29401709)
      Nucleic Acids Res. 2018 Jan 4;46(D1):D239-D245. (PMID: 29156006)
      Exp Clin Endocrinol Diabetes. 2004 Oct;112(9):542-4. (PMID: 15505764)
      Invest Ophthalmol Vis Sci. 2014 Mar 13;55(3):1509-18. (PMID: 24474278)
      Invest Ophthalmol Vis Sci. 2020 May 11;61(5):7. (PMID: 32392315)
      Nat Cell Biol. 2011 Apr;13(4):423-33. (PMID: 21423178)
      Nat Rev Drug Discov. 2017 Mar;16(3):203-222. (PMID: 28209991)
      Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5003-8. (PMID: 21383194)
      Eye Brain. 2018 Jun 28;10:37-45. (PMID: 29988739)
      Transl Vis Sci Technol. 2020 Feb 07;9(3):5. (PMID: 32704425)
      Ann Intern Med. 2003 Oct 21;139(8):635-41. (PMID: 14568851)
      Invest Ophthalmol Vis Sci. 2017 Feb 1;58(2):745-754. (PMID: 28146239)
      Cells. 2021 Mar 20;10(3):. (PMID: 33804633)
      Exp Eye Res. 2006 Apr;82(4):700-9. (PMID: 16289165)
      Arch Dis Child. 2002 Nov;87(5):446-8. (PMID: 12390930)
      Arch Ital Biol. 2011 Jun;149(2):283-92. (PMID: 21702001)
      Curr Neuropharmacol. 2015;13(3):294-303. (PMID: 26411962)
      J Transl Med. 2012 Nov 29;10:239. (PMID: 23190582)
      Ocul Surf. 2019 Jul;17(3):400-411. (PMID: 30959113)
      Invest Ophthalmol Vis Sci. 2016 Dec 1;57(15):6767-6775. (PMID: 27978558)
      NPJ Regen Med. 2021 Mar 26;6(1):16. (PMID: 33772031)
      Cancers (Basel). 2020 Jul 09;12(7):. (PMID: 32660045)
      Invest Ophthalmol Vis Sci. 2010 Sep;51(9):4492-9. (PMID: 20357207)
      Invest Ophthalmol Vis Sci. 2013 Aug 09;54(8):5343-52. (PMID: 23833064)
      Int J Mol Sci. 2020 Jan 19;21(2):. (PMID: 31963809)
      Cells. 2020 Sep 26;9(10):. (PMID: 32993109)
      Nanotoxicology. 2018 May;12(4):312-324. (PMID: 29463199)
      Front Endocrinol (Lausanne). 2018 Aug 03;9:402. (PMID: 30123182)
      Am J Pathol. 2021 Nov;191(11):1974-1985. (PMID: 34390680)
      Curr Opin Ophthalmol. 2012 Jul;23(4):296-302. (PMID: 22543481)
      Ophthalmology. 2018 Sep;125(9):1468-1471. (PMID: 29653861)
      Invest Ophthalmol Vis Sci. 2012 Nov 01;53(12):7476-83. (PMID: 23049092)
      Invest Ophthalmol Vis Sci. 2006 Oct;47(10):4323-9. (PMID: 17003422)
      N Engl J Med. 1998 Apr 23;338(17):1174-80. (PMID: 9554857)
      Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6377-86. (PMID: 26444718)
      Sci Rep. 2018 Jul 9;8(1):10306. (PMID: 29985466)
      Invest Ophthalmol Vis Sci. 2016 Nov 01;57(14):6210-6222. (PMID: 27849309)
      J Cell Physiol. 2017 Apr;232(4):717-724. (PMID: 27683068)
      Anticancer Agents Med Chem. 2016;16(1):7-19. (PMID: 26299662)
      Exp Eye Res. 2020 Sep;198:108138. (PMID: 32712184)
      Eur J Immunol. 2011 Jul;41(7):2029-39. (PMID: 21469088)
      Lancet. 1999 Jul 24;354(9175):307. (PMID: 10440316)
      Mutat Res. 2011 Dec 1;717(1-2):85-90. (PMID: 21402084)
      PLoS One. 2012;7(10):e46957. (PMID: 23077538)
      Acta Pharmacol Sin. 2018 Jul;39(7):1073-1084. (PMID: 29877320)
      Ocul Surf. 2017 Oct;15(4):660-669. (PMID: 28483646)
      PLoS One. 2013 Dec 20;8(12):e84425. (PMID: 24376808)
      Ophthalmology. 2018 Sep;125(9):1332-1343. (PMID: 29653858)
      Mol Vis. 2012;18:758-64. (PMID: 22509106)
      Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
      Invest Ophthalmol Vis Sci. 2000 Mar;41(3):692-702. (PMID: 10711683)
      Mol Med Rep. 2018 Sep;18(3):3203-3210. (PMID: 30066863)
      Ocul Surf. 2017 Jan;15(1):112-129. (PMID: 27789276)
      Br J Ophthalmol. 2020 Jan;104(1):127-135. (PMID: 30944103)
      Lancet. 2000 Nov 18;356(9243):1739-40. (PMID: 11095266)
      J Pharm Pharmacol. 2020 Dec;72(12):1732-1749. (PMID: 32783235)
      Cells. 2020 Jan 23;9(2):. (PMID: 31979244)
      Acta Ophthalmol. 2018 Feb;96(1):9-23. (PMID: 28271607)
      Exp Cell Res. 2017 Oct 1;359(1):10-16. (PMID: 28669664)
      Nucleic Acids Res. 2013 Jul;41(Web Server issue):W169-73. (PMID: 23680784)
      Tumour Biol. 2017 Jul;39(7):1010428317719577. (PMID: 28695771)
      Immunol Lett. 2012 Jan 30;141(2):165-8. (PMID: 22033216)
      Neural Regen Res. 2021 Sep;16(9):1740-1750. (PMID: 33510063)
      Exp Ther Med. 2021 Jun;21(6):599. (PMID: 33884037)
      Ophthalmology. 2000 Jul;107(7):1347-51; discussion 1351-2. (PMID: 10889110)
      Genomics Proteomics Bioinformatics. 2012 Oct;10(5):246-53. (PMID: 23200134)
      Invest Ophthalmol Vis Sci. 2000 Apr;41(5):1063-9. (PMID: 10752942)
      Mol Ther Nucleic Acids. 2015 Sep 15;4:e252. (PMID: 26372022)
    • Grant Information:
      Project n°230 "Identification of new compounds for treatment of eye and ear diseases" to EA Decree of Italian Ministry for Economical Progress 2018; 07_CONTRACT_DOMPE_TESSITORE for the project entitled 'MicroRNA expression analysis in response to different NGF bioformulations in in vitro corneal cell models' to AT Dompé (Italy)
    • Contributed Indexing:
      Keywords: biomarkers; corneal diseases; microRNA; neurotrophin signaling pathway; recombinant human NGF (rhNGF)
    • الرقم المعرف:
      0 (MIRN324 microRNA, human)
      0 (MIRN411 microRNA, human)
      0 (MicroRNAs)
      0 (Mirn337 microRNA, human)
      9061-61-4 (Nerve Growth Factor)
      EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
    • الموضوع:
      Date Created: 20220412 Date Completed: 20220413 Latest Revision: 20220415
    • الموضوع:
      20221213
    • الرقم المعرف:
      PMC8998691
    • الرقم المعرف:
      10.3390/ijms23073597
    • الرقم المعرف:
      35408969